Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011) Meeting Abstract
| Authors: | Moore, K. N.; Oza, A. M.; Colombo, N.; Oaknin, A.; Scambia, G.; Lorusso, D.; Banerjee, S.; Murphy, C.; Konner, J.; Lim, P.; Prasad-Hayes, M.; Monk, B. J.; Wang, J.; Birrer, M. J.; Vergote, I. B. |
| Abstract Title: | Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011) |
| Meeting Title: | ESMO Congress 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2022 Sep 9-13 |
| Meeting Location: | Paris, France |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-09-01 |
| Start Page: | S790 |
| End Page: | S791 |
| Language: | English |
| ACCESSION: | WOS:000866211600525 |
| DOI: | 10.1016/j.annonc.2022.07.660 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 532P -- Source: Wos |
